Clinical trial
Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer
NCT00402025 · BioVex Limited, Industry · Completed
Key facts
| NCT number | NCT00402025 |
|---|---|
| Title | Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer |
| Official title | Targeted Delivery of OncoVEX^GM-CSF by Endoscopic Ultrasound (EUS)-Guided Fine Needle Injection (FNI) in Patients With Irresectable Pancreatic Cancer: A Pilot Multinational Experiment on Safety and Proof of Concept |
| Lead sponsor | BioVex Limited, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Biological |
| Interventions | Talimogene Laherparepvec |
| Enrollment | 17 |
| Start date | Nov 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Nov 22, 2006 |
| Last update posted | Apr 15, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: